The First Food and Drug Administration–Indicated Drug for Postpartum Depression—Brexanolone

This Viewpoint discusses randomized clinical trials that have tested a new drug, brexanolone, to treat women with postpartum depression.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA psychiatry (Chicago, Ill.) Ill.), 2019-10, Vol.76 (10), p.1001-1002
Hauptverfasser:	Wisner, Katherine L, Stika, Catherine S, Ciolino, Jody D
Format:	Artikel
Sprache:	eng
Schlagworte:	beta-Cyclodextrins Clinical trials Depression, Postpartum - drug therapy Double-Blind Method Drug Combinations Drug delivery systems Female Humans Mental depression Postpartum depression Postpartum period Pregnanolone United States United States Food and Drug Administration Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This Viewpoint discusses randomized clinical trials that have tested a new drug, brexanolone, to treat women with postpartum depression.
ISSN:	2168-622X 2168-6238
DOI:	10.1001/jamapsychiatry.2019.1546